Schrödinger Reports Q4 Net Loss of $27.2M Despite Generating $56M in Revenue in 2023.
March 2, 2023
Trending News 🌧️
Schrödinger ($NASDAQ:SDGR), a leading provider of software for drug discovery and materials science, has recently reported its Q4 financial results for 2023. These costs amount to $7 million, resulting in an overall net loss of $27.2 million despite the significant revenue the company generated. This demonstrates the impact of increasing costs on a quarter-by-quarter basis and highlights the need for the company to stay focused on cost control while striving to grow its revenue base.
Schrödinger is continuing its focus on developing industry-leading software and services to help pharmaceutical and biotechnology companies accelerate their drug development efforts. The company is committed to maintaining a high level of innovation, while simultaneously controlling costs and focusing on achieving profitability in the near term.
Stock Price
Despite this less than favorable report, SCHRÖDINGER’s stock opened at $21.4 and closed at $21.7, a 1.1% increase from its last closing price of 21.5. Investors remained optimistic and seemed to be encouraged by SCHRÖDINGER’s potential for future success. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Schrödinger. More…
| Total Revenues | Net Income | Net Margin |
| 170.28 | -152.69 | -81.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Schrödinger. More…
| Operations | Investing | Financing |
| -114.48 | 56.38 | 2.85 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Schrödinger. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 661.99 | 198.86 | 6.5 |
Key Ratios Snapshot
Some of the financial key ratios for Schrödinger are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 30.2% | – | -82.7% |
| FCF Margin | ROE | ROA |
| -71.7% | -18.4% | -13.3% |
Analysis
We at GoodWhale performed an in-depth analysis of SCHRÖDINGER‘s wellbeing, to help investors make informed decisions. Our Risk Rating system has identified SCHRÖDINGER as a medium risk investment in terms of financial and business aspects. We have also detected one risk warning in the cashflow statement that could have an impact on the performance of SCHRÖDINGER. To see the complete list of risk warnings and recommendations, sign up for a free user account with GoodWhale. More…
Peers
Its competitors are Global Health Ltd, CardioComm Solutions Inc, and Simulations Plus Inc.
– Global Health Ltd ($ASX:GLH)
Global Health Ltd is a healthcare company with a focus on providing affordable and accessible healthcare products and services to underserved communities worldwide. The company has a market capitalization of 14.19 million as of 2022 and a return on equity of -19.3%. Global Health Ltd’s mission is to improve the health and wellbeing of people around the world by providing affordable and accessible healthcare products and services. The company’s products and services include primary care, maternal and child health, sexual and reproductive health, and non-communicable disease prevention and treatment. Global Health Ltd operates in over 50 countries and has a presence in more than 100 communities worldwide.
– CardioComm Solutions Inc ($TSXV:EKG)
CardioComm Solutions Inc is a medical device company that develops, manufactures and markets proprietary software solutions for the diagnosis and monitoring of cardiac patients. It has a market cap of 2.26M as of 2022 and a return on equity of -59.73%. The company’s products are used in hospitals, clinics and other healthcare settings around the world.
– Simulations Plus Inc ($NASDAQ:SLP)
Simulations Plus Inc. is a publicly traded company with a market capitalization of 811.3 million as of 2022. The company has a return on equity of 5.24%. Simulations Plus Inc. is a leading provider of simulation and modeling software for the pharmaceutical, biotechnology, and medical device industries. The company’s software is used by scientists to predict the behavior of complex systems, such as the human body, in order to improve the safety and efficacy of new drugs and medical devices.
Summary
S c h r ö d i n g e r r e p o r t e d a Q 4 n e t l o s s o f $ 2 7 . T h e c o m p a n y ’ s s t r o n g f i n a n c i a l p o s i t i o n i s l i k e l y a t t r i b u t e d t o t h e s u c c e s s o f i t s t w o f l a g s h i p p r o d u c t s : S c h r ö d i n g e r S u i t e a n d S c h r ö d i n g e r E n t e r p r i s e M o l e c u l a r M o d e l i n g , w h i c h g e n e r a t e m o s t o f t h e c o m p a n y ’ s l a b e l p r o f i t s a n d c o n t i n u e t o s h o w s t r o n g d e m a n d i n t h e m a r k e t . W h i l e S c h l ö d i n g e r ’ s c u r r e n t n e t l o s s s h o u l d b e v i e w e d w i t h c a u t i o n , i t s h i g h r e v e n u e g r o w t h a n d f i n a n c i a l s t r e n g t h i n d i c a t e s t h a t i t s f u t u r e p r o s p e c t s m a y b e q u i t e p r o m i s i n g.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
